<DOC>
	<DOCNO>NCT02340104</DOCNO>
	<brief_summary>The pupose study compare much baricitinib ( study drug ) get blood stream give single dose ( tablet form ) intravenous infusion ( injection give directly vein via small needle ) . Each participant study make four visit investigator site course 6 week .</brief_summary>
	<brief_title>A Study Measure Baricitinib ( LY3009104 ) Absorption Healthy Participants</brief_title>
	<detailed_description />
	<criteria>Are overtly healthy male female , determine medical history physical examination Male participant : agree use 2 reliable method birth control female partner childbearing potential study least 3 month follow last dose study drug Female participant : woman childbearing potential due surgical sterilization ( least 3 month surgical hysterectomy , bilateral oophorectomy without hysterectomy , bilateral tubal occlusion/ligation ) confirm medical history , menopause . Menopausal woman woman spontaneous amenorrhea least 12 month , induce medical condition anorexia nervosa take medication amenorrhea induce amenorrhea ( eg , oral contraceptive , hormone , gonadotropin release hormone , anti estrogen , selective estrogen receptor modulators , chemotherapy ) . Menopausal status confirm follicle stimulate hormone ( FSH ) level great 40 international unit per liter ( IU/L ) screening . Female participant sterilize tubal ligation require use contraception time screen 28 day last dose study drug Have body mass index 18.0 32.0 kilogram per meter square ( kg/m^2 ) , inclusive , screen Have venous access sufficient allow blood sampling ( IV ) administration study drug Are participants previously complete withdrawn study study investigate baricitinib , previously receive baricitinib Have know allergy baricitinib , related compound , component formulation , history significant atopy Have abnormality 12lead electrocardiogram ( ECG ) , opinion investigator , increase risk associate participate study Have history presence current cardiovascular , respiratory , hepatic , renal , gastrointestinal , endocrine , hematological , neurological disorder capable significantly alter absorption , metabolism , elimination drug ; constitute risk take study medication ; interfere interpretation data Have current recent history ( &lt; 30 day prior screen and/or &lt; 45 day prior day study drug administration ) clinically significant bacterial , fungal , parasitic , viral ( include rhinopharyngitis ) , mycobacterial infection Have symptomatic herpes zoster herpes simplex infection within 90 day prior dose Have absolute neutrophil count ( ANC ) less 2 × 109/liter ( L ) ( 2000 cell per microliter [ cells/μL ] ) screen day study drug administration . For abnormal value , single repeat allow Show evidence human immunodeficiency virus ( HIV ) infection and/or positive human HIV antibody Show evidence hepatitis C infection and/or positive hepatitis C antibody Show evidence hepatitis B infection and/or positive hepatitis B surface antigen Are woman pregnant lactate Have expose live vaccine within 12 week prior first dose expect need/receive live vaccine ( include herpes zoster vaccination ) course study Intend use overthecounter prescription medication and/or herbal supplement within 14 day prior dose study ( exception occasional paracetamol , permit discretion investigator ) , intend use vitamin supplement study drug administration discharge Clinical Research Unit ( CRU )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>